



July 13, 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Dear Sir/Madam,

**Sub: Certificate on Reconciliation of Share Capital
Audit for the quarter ended June 30, 2026**

Please find enclosed herewith the Certificate on Reconciliation of Share Capital Audit pursuant to the Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026 received from Mehta & Mehta, Company Secretaries in Practice.


Please take the same on your records.

Thanking you,

Yours faithfully,
For **AARTI PHARMALABS LIMITED**

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl. a/a.



COMPANY SECRETARIES

9Rajgir, Building, Office No. 1007, 10th floor, Korakendra, Borivali West, Mumbai – 400092
Tel.: +91 8956647802 / 9892960910. •E-mail: JPC@mehta-mehta.in. •Visit us: www.mehta-mehta.com

AUTHORISED AGENTS FOR TRADEMARK, COPYRIGHT AND PATENT

Date: 13th July, 2026

To

The Board of Directors,
Aarti Pharmalabs Limited
Plot No. 22/C/1 & 22/C/2, 1st Phase,
G.I.D.C., Vapi Valsad GJ 396195 IN


CERTIFICATE

We have examined the relevant books, registers, forms, documents and papers produced before us by **Aarti Pharmalabs Limited** (hereinafter referred as 'the Company') and **MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)**, its R & T Agents for issuing this certificate, in respect of **Reconciliation of Share Capital Audit as per Regulation 76** of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us and as shown by the records examined by us, we hereby certify the '**Reconciliation of Share Capital Audit Reports**' for the quarter ended **30th June, 2026** as per **Annexure I**.

For Mehta & Mehta,
Unique Code No.: P1996MH007500
Company Secretaries,

Partner
CS Monali Bhandari
UDIN: A027091H000813393





COMPANY SECRETARIES

Annexure – IRECONCILIATION OF SHARE CAPITAL AUDIT REPORT

1.	For Quarter Ended	30.06.2026
2.	ISIN	INE0LRU01027
3.	Face Value	Rs.5/-
4.	Name of the Company	Aarti Pharmalabs Limited
5.	Registered Office Address	Plot No 22/C/1 & 22/C/2, 1st Phase, GIDC Vapi 396195, Valsad, Gujarat
6.	Correspondence Address	204, Udyog Kshetra 2 nd Floor, Mulund Goregaon Link Road, Mulund West, Mumbai 400080
7.	Telephone & Fax Nos.	Tel.:- +91 22-6797 6666 Fax: +91 22-2565 3234
8.	Email address	investorrelations@aartipharmalabs.com
9.	Names of the Stock Exchanges where the company's securities are listed:	• BSE Limited • National Stock Exchange of India Limited

		Number of shares	% of Total Issued Capital
10.	Issued Capital	90679813	100
11.	Listed Capital (as per company records)	90657751	99.98
12.	Held in dematerialized form in NSDL	76689758	84.57
13.	Held in dematerialized form in CDSL	13967993	15.41
14.	Physical	0	0
15.	Total No. of shares (12+13+14)	90657751	99.98

16.	Reasons for difference if any, between,	(10&11)	22,062 equity shares allotted on June 24, 2026 under PSOP 2023 were in transit as on June 30, 2026. Listing and trading approvals were received from BSE and NSE on July 9, 2026, with trading effective July 10, 2026.
		(10&15)	22,062 equity shares allotted on June 24, 2026 under PSOP 2023 were in transit as on June 30, 2026. Listing and trading approvals were received from BSE and NSE on July 9, 2026, with trading effective July 10, 2026.
		(11&15)	NIL



Mehta & Mehta

COMPANY SECRETARIES

17. Certifying the details of changes in share capital during the quarter under consideration as per Table below: Yes

Particulars ***	No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	Is In-prin. approval pending for SE
ESOP	22062	Not applied for listing	No	Yes	Yes	No

*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction - Forfeiture, Any other (to specify).

18.	Register of Members is updated (Yes / No) If not, updated upto which date	Yes
19.	Reference of previous quarter with regards to excess dematerialized shares, if any.	NIL
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	N.A.
21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay: N.A.	

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	0	0	N.A.
Pending for more than 21 days	0	0	N.A.

22.	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mr. Jeevan Mondkar, Company Secretary and Compliance Officer Tel.: +91 22-6797 6666 Fax: +91 22-2565 3234
23.	Name, Address, Tel. & Fax No., Regn. no. of the Auditor	Mehta & Mehta, 201-206, Shiv Smriti Chambers, 2nd Floor, 49/A, Dr. Annie Besant Road, Above Corporation Bank, Worli, Mumbai-400 018. CS Jagdish Patel - FCS 2613; Contact No. 9324545141 CS Atul Mehta - FCS 5782; Contact No. 9820223978 CS Monali Bhandari - ACS 27091; Contact No. 9320887217
24.	Appointment of common agency for share registry work if yes (name & address)	YES MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West) Mumbai 400083, Maharashtra. SEBI Registration No.- INR000004058 Contact No.- 8108116767; Fax No.- 022-49186060 Email id- mumbai@in.mpms.mufg.com ; www.in.mpms.mufg.com
25.	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	NO

For Mehta & Mehta,
Unique Code No.: P1996MH007500
Company Secretaries,

Monali

Partner

CS Monali Bhandari

UDIN: A027091H000813393

Date: 13th July, 2026

